SCHEMBL3223370

SCHEMBL3223370

O=C(O)c1cc(-c2cccc(F)c2)ccn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 5/20 0.65
KDM4E B2RXH2 4/20 0.50
KDM4C Q9H3R0 3/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM5A P29375 2/20 0.50
KDM5B Q9UGL1 2/20 0.50
KDM6B O15054 1/20 0.50
TET3 O43151 1/20 0.50
KDM4A O75164 1/20 0.50
BBOX1 O75936 1/20 0.50
MAPT P10636 1/20 0.50
KDM5C P41229 1/20 0.50
ASPH Q12797 1/20 0.50
KDM4D Q6B0I6 1/20 0.50
TET2 Q6N021 1/20 0.50
ALKBH5 Q6P6C2 1/20 0.50
KDM7A Q6ZMT4 1/20 0.50
KDM8 Q8N371 1/20 0.50
TET1 Q8NFU7 1/20 0.50
EGLN2 Q96KS0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725162 0.83 KMO (0.62) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL7513922 0.83 KMO (0.71) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL30800092 0.83 KMO (0.71) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL24572141 0.82 KMO (0.62) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL486067 0.81 KMO (0.59) KMOKDM4EALDH1A1EGLN1DCLRE1B
SCHEMBL231979 0.81 KDM4E (0.61) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL29954072 0.81 KDM4E (0.61) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL28047487 0.81 ALDH1A1 (0.50) KMOALDH1A1MAPTGRM5TLR7
SCHEMBL3642765 0.81 KMO (0.56) KMOKDM4EKDM4CALDH1A1KDM5A
SCHEMBL2275018 0.80 KDM4E (0.59) KMOKDM4EKDM4CALDH1A1KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B KMO 3110/4885KDM4E 987/4885KDM4C 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.